SCHEMBL6599294

SCHEMBL6599294

CCOC(CN1C(=O)C(=NO)c2ccccc21)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 14/20 0.43
PKM P14618 4/20 0.43
KDM4E B2RXH2 3/20 0.43
KMT2A Q03164 3/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 8/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 1/20 0.40
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6599293 1.00 ALDH1A1 (0.43) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7614835 0.86 KMT2A (0.45) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7614839 0.86 KMT2A (0.45) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7612012 0.82 CES1 (0.56) ALDH1A1KMT2AMEN1AGTR1ALDH2
SCHEMBL7615847 0.81 KMT2A (0.49) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7615845 0.81 KMT2A (0.49) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7564533 0.80 CA12 (0.56) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7564529 0.80 CA12 (0.56) ALDH1A1PKMKDM4EKMT2ALMNA
SCHEMBL7589906 0.77 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2ALMNAMAPT
SCHEMBL9301105 0.77 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1156037-B1 CHONDRONGENESIS PROMOTORS AND INDOLIN-2-ONE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2004-12-01 EP disclosed
US-6716628-B2 CARTILAGE REPAIR AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-04-06 US disclosed
US-20030187054-A1 Preparations for chondrogenesis CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-10-02 US disclosed
US-20030119896-A1 Chondrogenesis promoters and indolin-2-one derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-06-26 US disclosed
US-6500854-B1 CHONDROCYTE PROLIFERATORS SUCH AS 1-(2,2-DIETHOXYETHYL)-3-(N'-(4-HYDROXYMETHYLPHENYL)UREIDO)-3-((4 -METHYLPHENYL)AMINO-CARBONYLMETHYL)INDOLIN-2-ONE FOR PROPHYLAXIS BONE DISORDERS CHUGAI SEI YAKU KABUSHIKI KAISHA (JP) 2002-12-31 US disclosed
EP-1266664-A1 PREPARATIONS FOR CHONDROGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-12-18 EP disclosed
EP-0685463-B1 INDOLIN-2-ONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2002-05-22 EP disclosed
EP-1156037-A1 CHONDRONGENESIS PROMOTORS AND INDOLIN-2-ONE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-11-21 EP disclosed
US-6207836-B1 Indolin-2-one derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-03-27 US disclosed
US-6127544-A 1-SUBSTITUTED-3-UREIDO-INDOLIN-2-ONES WHICH EXHIBIT SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM; SUCH AS FOR TREATMENT OF PEPTIC ULCERS, GASTRITIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-10-03 US disclosed
US-6114536-A ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES OF DIGESTIVE ORGANS, SUCH AS PEPTIC ULCER, GASTRITIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-09-05 US disclosed
US-6031111-A Indolin-2-one derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-02-29 US disclosed
CN-1046268-C Indolin-2-one derivatives CHUGAI PHARMACEUTICAL CO LTD (JP) 1999-11-10 CN disclosed
US-5952511-A EXHIBITS SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTOR WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO GASTRIN RECEPTOR ANTAGONISM AND USEFUL FOR TREATING PEPTIC ULCER, GASTRITIS, REFLUX ESOPHAGITIS AND ZOLLINGER-ELLISON SYNDROME CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1999-09-14 US disclosed
EP-0685463-A1 INDOLIN-2-ONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1995-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187054-A1 Preparations for chondrogenesis COL2A1, BMP2, COL1A1 ALDH1A1 104/4885PKM 3430/4885KDM4E 3290/4885
US-20030119896-A1 Chondrogenesis promoters and indolin-2-one derivatives SOX18, BMP2, EBP ALDH1A1 501/4885PKM 4154/4885KDM4E 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.